Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 66

Cited In for PubMed (Select 17404349)

1.

Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus.

Harris KB, McCarty DJ.

Ther Adv Endocrinol Metab. 2015 Feb;6(1):3-18. doi: 10.1177/2042018814558242. Review.

2.

Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes.

Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, Lee HC.

J Diabetes Investig. 2014 Sep;5(5):554-62. doi: 10.1111/jdi.12184. Epub 2013 Dec 22.

3.

Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.

Stranges P, Khanderia U.

Ther Adv Drug Saf. 2012 Aug;3(4):185-201. doi: 10.1177/2042098612454290. Review.

4.

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus.

Ji L, Onishi Y, Ahn CW, Agarwal P, Chou CW, Haber H, Guerrettaz K, Boardman MK.

J Diabetes Investig. 2013 Jan 29;4(1):53-61. doi: 10.1111/j.2040-1124.2012.00238.x. Epub 2012 Sep 14.

5.

Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes.

Inagaki N, Ueki K, Yamamura A, Saito H, Imaoka T.

J Diabetes Investig. 2011 Nov 30;2(6):448-56. doi: 10.1111/j.2040-1124.2011.00137.x.

6.

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks.

Kadowaki T, Namba M, Imaoka T, Yamamura A, Goto W, Boardman MK, Sowa H.

J Diabetes Investig. 2011 Jun 5;2(3):210-7. doi: 10.1111/j.2040-1124.2010.00084.x.

7.

Assessment of pancreatic β-cell function: review of methods and clinical applications.

Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL.

Curr Diabetes Rev. 2014 Jan;10(1):2-42. Review.

8.

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.

Arakaki RF, Blevins TC, Wise JK, Liljenquist DR, Jiang HH, Jacobson JG, Martin SA, Jackson JA.

Diabetes Obes Metab. 2014 Jun;16(6):510-8. doi: 10.1111/dom.12242. Epub 2013 Dec 29.

10.

Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.

DeFronzo RA, Eldor R, Abdul-Ghani M.

Diabetes Care. 2013 Aug;36 Suppl 2:S127-38. doi: 10.2337/dcS13-2011. No abstract available.

11.

Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.

Sun F, Yu K, Yang Z, Wu S, Zhang Y, Shi L, Ji L, Zhan S.

Exp Diabetes Res. 2012;2012:230624. doi: 10.1155/2012/230624. Epub 2012 Dec 26. Review.

12.

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP.

BMJ Open. 2013 Jan 24;3(1). pii: e001986. doi: 10.1136/bmjopen-2012-001986.

13.

Exenatide extended-release; clinical trials, patient preference, and economic considerations.

Doggrell SA.

Patient Prefer Adherence. 2013;7:35-45. doi: 10.2147/PPA.S30627. Epub 2013 Jan 9.

14.

Incretin hormones and the satiation signal.

Holst JJ.

Int J Obes (Lond). 2013 Sep;37(9):1161-8. doi: 10.1038/ijo.2012.208. Epub 2013 Jan 8. Review.

15.

Evolution of exenatide as a diabetes therapeutic.

Bhavsar S, Mudaliar S, Cherrington A.

Curr Diabetes Rev. 2013 Mar 1;9(2):161-93. Review.

16.

The evolving world of GLP-1 agonist therapies for type 2 diabetes.

Baynes KC.

Ther Adv Endocrinol Metab. 2010 Apr;1(2):61-7. doi: 10.1177/2042018810375414.

17.

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.

Tobin GS, Cavaghan MK, Hoogwerf BJ, McGill JB.

Int J Clin Pract. 2012 Dec;66(12):1147-57. doi: 10.1111/ijcp.12032. Epub 2012 Oct 14. Review.

18.

The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus.

Brice KR, Tzefos MK.

Clin Med Insights Endocrinol Diabetes. 2011;4:13-24. doi: 10.4137/CMED.S4086. Epub 2011 Mar 14.

19.

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence.

Meloni AR, DeYoung MB, Lowe C, Parkes DG.

Diabetes Obes Metab. 2013 Jan;15(1):15-27. doi: 10.1111/j.1463-1326.2012.01663.x. Epub 2012 Aug 1. Review.

20.

Alterations in energy balance following exenatide administration.

Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA.

Appl Physiol Nutr Metab. 2012 Oct;37(5):893-9. doi: 10.1139/h2012-068. Epub 2012 Jun 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk